The pharma index has hugely underperformed the Sensex in CY17 owing to regulatory overhang and FDA issues
Astec LifeSciences continues to head north as promoters jack up holding
Post demonetisation, mid-cap cement stocks look poised to recover lost ground
Promoter KV Bala has been on a stock mopping spree in Indowind
Techno Electric’s strong execution track record and financial discipline makes it a company to watch out for
Will Trident’s accelerated push in the home-textiles business sustain its next leg of growth?
Will investment trusts put an end to the funding woes of infrastructure companies?
Leveraged infra companies are banking on a new instrument to turn around their fortunes
What makes Bharti Infratel a strong incumbent in the telecom tower business
Richard Iley, chief economist, emerging markets, BNP Paribas, talks about the prospects for the Indian market
Jim Rogers on why China remains a better investment bet despite the slowdown
In the final part, Raamdeo Agrawal stresses on zero distraction when digging deeper to find great opportunities
In the first of a two-part interview, Raamdeo Agrawal points out the drawback of the 100X study and the attributes of extraordinary growth
In the final installment, ASK group’s Bharat Shah explains why using P/E to derive value is plain stupid
In the second of a three-part interview, ASK group’s Bharat Shah elaborates on the investing lessons learnt over a 29-year-long career
